The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Efficacy of Methylphenidate for Adults with Attention-Deficit Hyperactivity Disorder: A Meta-Regression Analysis
Abstract
Background The efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder (ADHD) shows wide between-study variability, which yields heterogeneous results in meta-analysis. The reasons for this variability have not been comprehensively investigated.Objectives To determine the influence of treatment-related covariates of methylphenidate for adults with ADHD by means of meta-analysis. Clinical and methodological moderators and clinical trial reporting quality were also collected to control for their potential confounding effect.Methods We searched for randomized, placebo-controlled clinical trials investigating the efficacy of methylphenidate for adults with ADHD. The study outcome was the efficacy of methylphenidate for reducing ADHD symptom severity. Treatment-related covariates included dose, type of drug-release formulation (formulations with a continuous drug release vs those with a non-continuous drug release), dose regimen (fixed vs flexible) and treatment length. Clinical (presence of co-morbid substance use disorders [SUD]) and methodological (design and rater) covariates were also collected, in addition to clinical trial reporting quality. The standardized mean difference (SMD) was calculated for each study. The analysis of the influence of methylphenidate effect modifiers was performed by means of random-effects meta-regression.Results Eighteen studies were included. Dose, type of formulation and SUD appeared to modify the efficacy of methylphenidate in the bivariate analysis. These variables were included in a multivariate meta-regression, which showed that methylphenidate, at an average dose of 57.4 mg/day, delivered by means of non-continuous-release formulations, had a moderate effect on ADHD symptoms compared with placebo (SMD 0.57-0.58). A dose-response relationship was found, indicating that efficacy could be increased by SMD 0.11-0.12 for every 10 mg increment of methylphenidate. Continuous-release formulations and co-morbid SUD appeared to reduce the efficacy of methylphenidate. Nevertheless, the effect of treatment formulation may have been confounded by co-morbid SUD, since all studies using this continuous-release formulation were conducted in dual ADHD-SUD patients. No residual heterogeneity was found.Conclusions This study shows that methylphenidate improves ADHD symptoms in adults in a dose-dependent fashion. The efficacy of methylphenidate appears to be reduced in patients with co-morbid SUD. It is unclear whether methylphenidate efficacy is influenced by the type of formulation, because the effect of this covariate is confounded by that of co-morbid SUD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Psychostimulants, including methylphenidate (MPH), dextroamphetamine, and mixed amphetamine salts are not only efficacious in the treatment of ADHD in children and adolescents but also, in adults.11,12”
From Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD (2014) · cites this paper as [11]
In the citing paper
“The clinical effectiveness of stimulants such as methylphenidate in the treatment of ADHD suggests a putative role for both dopamine and noradrenaline in the manifestation of the disorder (Castells et al., 2011).”
From A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment (2013) · cites this paper as Castells et al., 2011
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Systematic Reviews in Health Care : Meta-Analysis in Context
Egger, M., Smith, G. D., & Altman, D. G. (2000) · Cited by 2,312
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
Systematic Review: Why sources of heterogeneity in meta-analysis should be investigated
Thompson, S. G. (1994) · BMJ · doi:10.1136/bmj.309.6965.1351 · Cited by 1,017
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.12.1792 · Cited by 950
BIEDERMAN, J., MONUTEAUX, M. C., MICK, E., SPENCER, T., WILENS, T. E., SILVA, J. M., SNYDER, L. E., & FARAONE, S. V. (2006) · Psychological Medicine · doi:10.1017/s0033291705006410 · Cited by 850
ATTENTION-DEFICIT HYPERACTIVITY DISORDER IN ADULTS
Wender, P. H. (1998) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70039-3 · Cited by 728
Solanto, M. V. (1998) · Behavioural Brain Research · doi:10.1016/s0166-4328(97)00175-7 · Cited by 677
3-year follow-up of the NIMH MTA study
JENSEN, P. S., ARNOLD, L. E., SWANSON, J. M., VITIELLO, B., ABIKOFF, H. B., GREENHILL, L. L., HECHTMAN, L., HINSHAW, S. P., PELHAM, W. E., WELLS, K. C., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3180686d48 · Cited by 643
Research works printed but not linked: 2
- Döpfner, 2004, Eur Child Adolesc Psychiatry, 13, I93
- Faraone, 2006, Med Gen Med, 8, 4
Cited by
Sorted by citations
Items 101–197 of 197
Linderkamp, F., & Lauth, G. W. (2011) · Verhaltenstherapie · doi:10.1159/000332429 · Cited by 18
Victor, M. M., Rovaris, D. L., Salgado, C. A. I., Silva, K. L., Karam, R. G., Vitola, E. S., Picon, F. A., Contini, V., Guimarães-da-Silva, P. O., Blaya‐Rocha, P., et al. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000091 · Cited by 17
“A substantial amount of evidence documents the efficacy of immediate and modified-release formulations of methylphenidate hydrochloride (MPH) in adults with ADHD.(3) Indeed, MPH is actually a first line treatment of inattention, hyperactivity, and impulsivity in adults with ADHD.”
BackgroundInfluentialExtended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults
Boesen, K., Paludan‐Müller, A. S., Gøtzsche, P. C., & Jørgensen, K. J. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012857.pub2 · Cited by 23
Zhang, Z., Chang, X., Zhang, W., Yang, S., & Zhao, G. (2023) · Journal of Attention Disorders · doi:10.1177/10870547231154897 · Cited by 18
“In the aspect of medication treatment of ADHD symptoms, one study (Castells et al., 2011) found that methylphenidate has an almost medium effect size (SMD = 0.49), and another study (Cunill et al., 2013) concluded that atomoxetine has a small to medium effect (SMD = −0.33).”
ResultInfluentialPierre, M., Cogez, J., Lebain, P., Loisel, N., Lalevée, C., Bonnet, A. L., Sayette, V. D. L., & Viader, F. (2019) · Revue Neurologique · doi:10.1016/j.neurol.2018.09.021 · Cited by 14
Qu, S., Wang, P., Wang, M., Li, C., Dong, X., Xu, L., & Han, F. (2022) · Sleep Medicine · doi:10.1016/j.sleep.2022.05.016 · Cited by 14
Shift Work and Sleep: Optimizing Health, Safety, and Performance
(2011) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0b013e31821aec20 · Cited by 23
Development of the Korean Practice Parameter for Adult Attention-Deficit/Hyperactivity Disorder
Bahn, G. H., Lee, Y. S., Yoo, H. K., Kim, E., Park, S., Han, D. H., Hong, M., Kim, B., Lee, S. I., Bhang, S., et al. (2019) · Journal of korean Academy of Child and Adolescent Psychiatry · doi:10.5765/jkacap.190030 · Cited by 14
Vold, J. H., Halmøy, A., Chalabianloo, F., Pierron, M. C., Løberg, E., Johansson, K. A., & Fadnes, L. T. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04980-w · Cited by 13
Integrative proteomics and pharmacogenomics analysis of methylphenidate treatment response
da Silva, B. S., Leffa, D. T., Beys-da-Silva, W. O., Torres, I. L. S., Rovaris, D. L., Victor, M. M., Rohde, L. A., Mota, N. R., Oliveira, C. D., Berger, M., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0649-5 · Cited by 12
Effects of Methylphenidate on the Dopamine Transporter and Beyond
Zetterström, T., Quansah, E., & Grootveld, M. C. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_333 · Cited by 11
Paraskevopoulou, M. D., van Rooij, D., Batalla, A., Chauvin, R. J., Luijten, M., Schene, A. H., Buitelaar, J. K., & Schellekens, A. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00896-1 · Cited by 13
“ADHD patients with comorbid SUD start substance use at an earlier age, progress more rapidly from recreational use to SUD [9] and respond poorly to SUD and ADHD treatment, compared to SUD-only [4, 9] and ADHD-only patients [10], respectively.”
BackgroundExtended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults
Boesen, K., Danborg, P. B., Gøtzsche, P. C., & Jørgensen, K. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012857 · Cited by 11
Cunill, R., Castells, X., González-Pinto, A., Arrojo, M., Bernardo, M., Saiz, P., Flórez, G., Torrens, M., Tirado-Muñoz, J., Fonseca, F., et al. (2021) · Adicciones · doi:10.20882/adicciones.1569 · Cited by 13
“…in the therapeutic armamentarium, patients with dual ADHD and a SUD diagnosis are rarely treated with ADHD medications in clinical practice (Castells, Ramos-Quiroga, Bosch, Nogueira & Casas, 2011a; Castells et al., 2011b; Cunill & Castells, 2016a; Cunill, Castells, Tobias & Capellà, 2016b).”
Neonatal methylphenidate does not impair adult spatial learning in the Morris water maze in rats
Amos‐Kroohs, R. M., Williams, M. T., & Vorhees, C. V. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.07.013 · Cited by 10
“2–82 mg/day [11]; MPD abusers take much higher doses.”
BackgroundAdult attention deficit hyperactivity disorder: translating research into practice
Coogan, A. N., Dobrean, A., Donev, R., Mateescu, L., Müller, U., Thome, J., & Voinescu, B. (2012) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-012-0073-7 · Cited by 10
“The most recent meta-analysis of 17 methylphenidate studies reports a medium effect size of 0.48 (Castells et al. 2011) another recent meta-analysis reports numbers needed to treat (NNT) around 3 for psychostimulants and around 5 for atomoxetine (Faraone and Glatt 2010), these are some of the…”
BackgroundInfluentialSelaskowski, B., Staerk, C., Braun, N., Matthies, S., Graf, E., Colla, M., Jacob, C., Sobanski, E., Alm, B., Roesler, M., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.03.049 · Cited by 11
LORETA Neurofeedback in College Students with ADHD
Decker, S. L., Roberts, A. M., & Green, J. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801291-8.00014-5 · Cited by 9
“Both behavioral (Pelham & Fabiano, 2008) and psychopharmacological interventions (i.e., stimulant medication) (Bitter, Angyalosi, & Czobor, 2012; Castells et al., 2011; Faraone & Biederman, 2002; Faraone, Spencer, Aleardi, Pagano, & Biederman, 2004) have demonstrated effectiveness in treating ADHD.”
Connor, C., Hamilton, J., Robison, L. S., Hadjiargyrou, M., Komatsu, D. E., & Thanos, P. K. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210127120411 · Cited by 9
Are the effects of methylphenidate uncertain?
Cortese, S. (2018) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2018.16 · Cited by 9
“…efficacy of MPH for the reduction of ADHD symptoms in the short term (e.g. Schachter et al. 2001; Van der Oord et al. 2008; Koesters et al. 2009; Castells et al. 2011), a recent systematic review and metaanalysis by a Cochrane group led by Storebø (Storebo et al. 2015) questioned the evidence…”
BackgroundBerger, C., Müller‐Godeffroy, J., Marx, I., Reis, O., Buchmann, J. A., & Dück, A. (2018) · Brain and Behavior · doi:10.1002/brb3.1155 · Cited by 9
Sanz, J. A., Schwalbe, M., Pereira, R. R., Permentier, H. P., & Aidy, S. E. (2021) · Pharmaceuticals · doi:10.3390/ph14080733 · Cited by 7
“Thus, ADHD is mainly treated with amphetamine-like psychostimulants that improve symptoms by increasing the levels of dopamine and norepinephrine neurotransmitters in the brain.”
BackgroundInfluentialShould we Keep on? Looking into Pharmacogenomics of ADHD in Adulthood from a Different Perspectives
Rovaris, D. L., Mota, N. R., da Silva, B. S., Girardi, P., Victor, M. M., Grevet, E. H., Bau, C. H. D., & Contini, V. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.95 · Cited by 7
Paraskevopoulou, M. D., van Rooij, D., Schene, A. H., Scheres, A., Buitelaar, J. K., & Schellekens, A. (2020) · European Addiction Research · doi:10.1159/000509147 · Cited by 7
TDA/H, trouble de l’enfance ou de l’âge adulte ?
Ilario, C., Alt, A., Bader, M., & Sentissi, O. (2019) · L Encéphale · doi:10.1016/j.encep.2019.05.004 · Cited by 7
Coetzee, C., Schellekens, A., Truter, I., & Meyer, A. (2022) · European Addiction Research · doi:10.1159/000526386 · Cited by 6
Prescriptions hors AMM supervisées de méthylphénidate dans le TDAH de l’adulte
Carton, L., Dondaine, T., Deheul, S., Marquié, C., Brigadeau, F., Amad, A., Devos, D., Danel, T., Bordet, R., Cottencin, O., et al. (2018) · L Encéphale · doi:10.1016/j.encep.2018.05.008 · Cited by 6
Gomes, A. C. D. C. N., Bellin, C. S., Dias, S. D. S., de Rosa, T. D. Q., de Araújo, M. P., Miraglia, S. M., Mendes, T. B., & Vendramini, V. (2022) · Andrology · doi:10.1111/andr.13277 · Cited by 6
Hautmann, C., Rothenberger, A., & Döpfner, M. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-219 · Cited by 6
“These findings are in line with the assumption of a linear dose– response relationship between MPH treatment and ADHD symptoms, as has previously been demonstrated [50,51].”
ResultGül, A. (2019) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.14744/dajpns.2019.00020 · Cited by 4
“SUD patients with ADHD are reported to have worse treatment outcomes for both disorders (25,26).”
BackgroundMartin-Key, N. A., Stevenson, A., & Roy, P. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001350 · Cited by 5
Oortmerssen, K. V. E., Konstenius, M., & Schoevers, R. A. (2014) · Springer eBooks · doi:10.1007/978-3-642-45375-5_13 · Cited by 5
Attention deficit hyperactivity disorder in adults
Pitts, M. E. (2014) · Nurse Prescribing · doi:10.12968/npre.2014.12.1.18 · Cited by 5
Treatment of Comorbid Substance Use Disorders and ADHD in Youth
Carrellas, N. W., Wilens, T. E., & Anselmo, R. (2016) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-016-0072-y · Cited by 6
Attention-Deficit Hyperactivity Disorder and Autism Spectrum Disorder
Cortese, S. (2016) · Springer eBooks · doi:10.1007/978-3-319-29695-1_6 · Cited by 5
Sleep Disturbances in Attention-Deficit/Hyperactivity Disorder
Cortese, S., & Lecendreux, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-24288-2.00141-0 · Cited by 5
Medikamentöse Therapie der Aufmerksamkeitsdefizit‑/Hyperaktivitätsstörung im Erwachsenenalter
Retz, W., Retz‐Junginger, P., Davydenko, S., & Rösler, M. (2020) · Der Nervenarzt · doi:10.1007/s00115-020-00891-3 · Cited by 5
The Effects of Drug Treatments for ADHD in Measures of Cognitive Performance
Higgins, G. A., & Silenieks, L. B. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_341 · Cited by 4
Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults
Cândido, R. C. F., Golder, S., de Pádua, C. A. M., Perini, É., & Junqueira, D. R. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013011 · Cited by 3
Attention-deficit hyperactivity disorder and exposure to nature in college students
Thal, L. (2014) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/44338 · Cited by 4
“Evidently, immediate-release medication is more efficacious in adults for ADHD symptoms (Castells et al. 2011), although this requires multiple doses per day and a higher chance of missing a dose (Swanson, 2003).”
BackgroundResultInfluentialKhalil, D. M., Sherra, K., Abuhegazy, H. M. M., Nagda El masry, M., Kamel, A., Azim, K. A. A., Shahdah, M., & Melegy, A. E. (2016) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2016/669 · Cited by 3
Correll, C. U., Starling, B. R., & Huß, M. (2021) · CNS Spectrums · doi:10.1017/s1092852921000341 · Cited by 3
Contrasting expectancy effects with objective measures in adults with untreated ADHD during QbTest
Löhman, M., Domingo, B., Östlund, M., & Jansson, L. (2023) · Scandinavian Journal of Psychology · doi:10.1111/sjop.12906 · Cited by 3
Teodorini, R. D., Rycroft, N., & Smith-Spark, J. H. (2024) · Brain and Behavior · doi:10.1002/brb3.3403 · Cited by 3
“The effectiveness of CEDs such as methylphenidate in treating ADHD is well-recognized (Castells et al., 2011; Van der Oord et al., 2008).”
BackgroundYuan, A., King, N. E., Kharas, N., Yang, P. B., & Dafny, N. (2022) · Physiology & Behavior · doi:10.1016/j.physbeh.2022.113845 · Cited by 3
Pharmacotherapy of ADHD in Adults
Rösler, M., Retz, W., & Turner, D. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_254 · Cited by 3
Psychopharmakotherapie – klinisch-empirische Grundlagen
Volz, H., Kasper, S. F., & Möller, H. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_31 · Cited by 3
Sanz, J. A., Maho, W., Pereira, R. R., Permentier, H. P., & Aidy, S. E. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.06.189191 · Cited by 3
Cortical gyrification predicts initial treatment response in adults with ADHD
Laatsch, J., Stein, F., Maier, S. J., Matthies, S., Sobanski, E., Alm, B., van Elst, L. T., Krug, A., & Philipsen, A. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03681-0 · Cited by 2
Hout, M. C. V., & Foley, M. (2013) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2013.8 · Cited by 2
Lipps, A. J., & Jang, K. (2020) · Journal of Evidence-Based Social Work · doi:10.1080/26408066.2020.1819927 · Cited by 2
“Such a study was, in fact, conducted by (Castells et al., 2011).”
BackgroundMethodInfluentialDaily Symptom Profiles of Children With ADHD Treated With Modified-Release Methylphenidate
Hautmann, C., Rothenberger, A., & Döpfner, M. (2013) · Journal of Attention Disorders · doi:10.1177/1087054713502233 · Cited by 2
“As the effect of MPH is dose dependent (Castells et al., 2011), this finding is consistent with expectations and also might be interpreted that symptom severity in this subgroup cannot simply be regarded as a sign of undermedication.”
ResultAdult ADHD: an area lacking in clinical research?
Ramos‐Quiroga, J. A., & Sagüés, M. O. (2013) · Clinical Investigation · doi:10.4155/cli.13.69 · Cited by 2
Self-citationKlungsøyr, O., & Fredriksen, M. (2017) · Open Journal of Statistics · doi:10.4236/ojs.2017.76070 · Cited by 2
“Short term effect of medication for treatment of ADHD is well documented [3] [4] [5] [6].”
BackgroundHerrera-Morales, W. V., Ramı́rez-Lugo, L., Cauich-Kumul, R., Murillo‐Rodríguez, E., & Núñez-Jaramillo, L. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220509155413 · Cited by 3
Tockhorn‐Heidenreich, A., & Televantou, F. (2015) · Pharmacoeconomics open access · doi:10.4172/2472-1042.1000104 · Cited by 1
“A meta-analysis has failed to show a reduction in ADHD symptoms with methylphenidate in patients with comorbid substance use disorder [53], although one randomised trial has shown moderate efficacy [54].”
BackgroundHeterogeneity among included studies
Mokhtari, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13428-9.00013-6 · Cited by 1
Cocaine Dependence and Attention Deficit Hyperactivity Disorder
Crunelle, C., & Matthys, F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803750-8.00039-7 · Cited by 2
Medikamentöse Therapie der ADHS bei Erwachsenen
Rösler, M., & Retz, W. (2020) · PSYCH up2date · doi:10.1055/a-0891-1940 · Cited by 1
“[10] Castells X, Ramos-Quiroga JA, Rigau D et al.”
BackgroundPharmacotherapy of ADHD in Adults
Rösler, M., Retz, W., & Turner, D. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_254-1 · Cited by 1
Boesen, K., Jørgensen, K., & Gøtzsche, P. (2021) · medRxiv · doi:10.1101/2021.12.08.21267468
Somkuwar, S. S. (2013) · UKnowledge (University of Kentucky)
Emch, M. (2015) · Repositori digital de la UPF (Universitat Pompeu Fabra)
Addressing common misconceptions about attention deficit hyperactivity disorder in adults
Müller, U., & Asherson, P. (2012) · Neuropsychiatry · doi:10.2217/npy.12.22
Employment Acquisition, Work Productivity, and Job Retention
London, J. B., Molinero, A. M., & McCue, M. P. (2011)
Attention Deficit Hyperactivity Disorder, Substance Use Disorders, and Heroin Addiction
Salman, S., Idrees, J., Anees, M., & Idrees, F. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800213-1.00096-1
Modediagnose oder tatsächlich mehr Patienten?
Mehler‐Wex, C., & Deimel, W. (2013) · NeuroTransmitter · doi:10.1007/s15016-013-0045-y
Seals, N. (2013) · OpenSIUC (Southern Illinois University Carbondale)
Geller, L. (2021) · doi:10.1002/9781119558378.ch24
The Neural Substrates of Response Inhibition in Attention Deficit Hyperactive Disorder (ADHD)
Bhaijiwala, M. (2016) · TSpace (University of Toronto)
Attention and ADHD: Measurement and Medication
Saliba, K. (2014) · TSpace (University of Toronto)
ADHS im Erwachsenenalter und substanzbezogene Störungen
Schecke, H., & Mette, C. (2020) · Springer eBooks · doi:10.1007/978-3-662-45995-9_23-1
Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung im Erwachsenenalter
Sobanski, E., Alm, B., & Thome, J. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_85
Psychopharmakotherapie – klinisch-empirische Grundlagen
Volz, H., Kasper, S. F., & Möller, H. ‐. (2015) · Springer eBooks · doi:10.1007/978-3-642-45028-0_31-1
(2021) · Wiley eBooks · doi:10.1002/9781119558378.ref
(2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328352dd8d
UKAAN (2013) · doi:10.1007/978-1-908517-79-1_7
Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) des Erwachsenenalters
Ebert, D., Philipsen, A., & Hesslinger, B. (2019) · Psychische Erkrankungen · doi:10.1016/b978-3-437-22485-0.00025-7
Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung im Erwachsenenalter
Sobanski, E., Alm, B., & Thome, J. (2015) · Springer eBooks · doi:10.1007/978-3-642-45028-0_85-1 · Cited by 2
Pharmakotherapie von Erwachsenen mit ADHS in der Praxis
Ahlers, E. (2022) · DNP – Die Neurologie & Psychiatrie · doi:10.1007/s15202-022-4916-6
Jansson, L., Löhman, M., Östlund, M., & Domingo, B. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05231-8
Trouble déficitaire de l’attention avec hyperactivité et addictions
Rolland, B., Icick, R., Ménard, O., Kammerer, E., Carton, L., & Jurek, L. (2023) · Elsevier eBooks · doi:10.1016/b978-2-294-77934-3.00030-5
Jerônimo, G. F., de Almeida, T. S. F., Jerônimo, A. F. D. A., Farias, A. C. A. D. O., Xavier, G. T., de Espíndola, C. A., de Moraes, A. R. C. S., Botêlho, S. F. A. G., Lima, H. L. D. P., Santos, E. C., et al. (2024) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2024v6n6p40-57
Schoeman, R., Lai, E. Y., Nel, A.-M., Gani, M., Fulat, M. A., & Mahomed, A. (2024) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v30i0.2267
Grundlagen der Diagnostik und Therapie
(2024) · Elsevier eBooks · doi:10.1016/b978-3-437-22487-4.16001-0
Vold, J. H., Halmøy, A., Chalabianloo, F., Pierron, M. C., Løberg, E.-M., Johansson, K. A., & Fadnes, L. T. (2023) · Figshare · doi:10.6084/m9.figshare.23606900
Vold, J. H., Halmøy, A., Chalabianloo, F., Pierron, M. C., Løberg, E.-M., Johansson, K. A., & Fadnes, L. T. (2023) · Figshare · doi:10.6084/m9.figshare.23606894
Vold, J. H., Halmøy, A., Chalabianloo, F., Pierron, M. C., Løberg, E.-M., Johansson, K. A., & Fadnes, L. T. (2023) · Figshare · doi:10.6084/m9.figshare.23606897
Utage, P., Boddu, D. B., Majhi, S. K., Devasia, D., Saha, S., Patanjali, S., Godbole, S., Agarwalla, S. K., & Sharma, A. (2026) · Cureus · doi:10.7759/cureus.112111
“While methylphenidate demonstrates robust effect sizes in controlled trials, its use is associated with appetite suppression, insomnia, growth attenuation, and cardiovascular effects [30].”
Psychopharmakotherapie – klinisch-empirische Grundlagen
Kasper, S. F., Hasan, A., & Möller, H. (2026) · Springer Reference Medizin · doi:10.1007/978-3-642-45028-0_31-2
Victor, M. M. (2014) · Americanae (AECID Library)
Metadata
- Authors
- Castells, X., Ramos-Quiroga, J. A., Rigau, D., Bosch, R., Nogueira, M., Vidal, X., & Casas, M.
- Affiliations
- Vall d'Hebron Hospital Universitari (ES)
- Universitat Autònoma de Barcelona (ES)
- Venue
- CNS Drugs
- Published
- 2011-02
- Volume
- 25
- Issue
- 2
- Pages
- 157-169
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W2330451900
- Semantic Scholar
- 10b8118ac40b4e13bd9ab65989f9149be93a6f39
- Cited by
- 197
- References
- 62
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 5 · 2023: 10 · 2022: 14 · 2021: 14 · 2020: 16 · 2019: 11 · 2018: 15 · 2017: 21 · 2016: 15 · 2015: 15 · 2014: 20 · 2013: 17 · 2012: 14
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Departament de Salut, Generalitat de Catalunya
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- methylphenidate, adult ADHD, dose-response relationship, substance use disorders, ADHD symptom severity, effect modifiers, meta-regression, trial reporting quality, treatment duration, dosing regimen, confounding by comorbidity, standardized mean difference
- MeSH terms
- Adult, Attention Deficit Disorder with Hyperactivity, Delayed-Action Preparations, Dose-Response Relationship, Drug, Humans, Methylphenidate, Regression Analysis, Comorbidity, Randomized Controlled Trials as Topic, Treatment Outcome, Substance-Related Disorders, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
